30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Zimmer Biomet Reports 2Q16 Revenue -

ORTHOWORLD estimates Zimmer Biomet (ZBH) 2Q16 orthopaedic revenue of US $1,770.5MM, +3.1% from 2Q15 as-reported.

ORTHOWORLD estimates 2Q16 segment sales and growth on an as-reported basis, as follows.

  • Joint Reconstruction $1,273.5MM, +3.1%
    • Hips $477.2MM, +3.4%
    • Knees $696.9MM, +2.2%
    • Extremities Recon $99.4MM, +8.5%
  • Trauma $134.6MM, +9.0%
  • Arthroscopy/Soft Tissue Repair $31.2MM, +10.8%
  • Spine $73.5MM, +2.1%
  • Orthobiologics $70.8MM, +3.1%
  • Other $186.9MM, -1.8% (CMF, Bone Healing, Forgings and Accelero)

 

Hip growth was supported by Taperloc Complete, the revision portfolio, Vivacit-E and E1 advanced bearings; the ZBH salesforce is also focused on increasing adoption of recent launches, such as Echo Bi-Metric Microplasty Stem, Arcos One-piece Revision and the G7 Dual Mobility Construct.

Cross-selling opportunities continued in knees, led by Persona and Vanguard 360. ZBH marked the 40-year anniversary for the Oxford Partial knee during the quarter. The system has been used in >600K surgeries in 50 countries, to date.

“Attractive” growth in Arthroscopy/Soft Tissue arose from contributions of Gel-One Hyaluronate Injection, Subchondroplasty, Quattro Link Knotless Anchors and the XTRAFIX system.

Leadership noted a sequential quarterly improvement in trauma segment performance. Within 2Q, ZBH launched next-gen enhancements to its OSS Orthopaedic Salvage System.

Spine sales were supported by steady revenues for the Polaris Spinal System and expansions to Timberline Lateral Fusion, both platforms acquired with Biomet.

On the M&A front, ZBH completed acquisitions of Cayenne Medical in 2Q, then Medtech and LDR in 3Q, supporting its abilities to offer customers a complete and diverse product portfolio.

Also in 3Q, ZBH debuted the limited U.S. launch of Signature Solutions™, a suite of clinical services and technologies to assist hospitals and medical practices with the transition to value-based healthcare models. Leadership noted that a previous launch, Z23 for outpatient knee procedure support, is integrated within this offering.

Finally, leadership observed that while they take all competitive launches seriously, nothing about the Medtronic/Responsive Orthopedics acquisition should be notably game-changing to the marketplace.

Sources: Zimmer Biomet, Inc.; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.